WOCKHARDT LTD. - 532300 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on 31st March, 2023. WOCKHARDT LTD. - 532300 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd WOCKHARDT LTD. - 532300 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on March 31, 2023 for Humuza Consultants through Themisto Trustee Company Pvt Ltd WOCKHARDT LTD. - 532300 - Closure of Trading Window
The Trading Window of the Company will be closed from 1st April, 2023 until 48 (Forty-Eight) hours after the declaration of financial results of the Company for the financial year ended 31st March, 2023.
Wockhardt's former official settles insider trading case with Sebi
A former official of drug maker Wockhardt on Thursday settled with Sebi a case pertaining to alleged non-disclosure of adverse observations made by the USFDA about the company's manufacturing facility to the exchanges in 2013. Vijay Khetan, who was the compliance officer of Wockhardt, paid Rs 27.06 lakh towards the settlement charges to the capital markets regulator for the alleged violations of insider trading rules, the Securities and Exchange Board of India (Sebi) said in an order. The order came after Khetan proposed to settle the pending proceedings through a settlement order. Sebi, through a show cause notice in September 2022, alleged that Khetan, being the compliance officer of Wockhardt at the relevant point of the time, had failed to ensure disclosure of price sensitive information immediately to stock exchanges. Therefore, he allegedly violated the code of conduct specified under the insider trading rules, as per the show cause notice. It was also alleged that Wockhardt
Wockhardt plans to roll out two vaccines from UK plant in a year
Drug firm Wockhardt plans to roll out two vaccines within a year from its UK-based facility as part of a tie-up with Serum Institute of India, a top company official said. Last year, a Wockhardt unit tied up with a subsidiary of Serum Institute of India to set up a vaccine manufacturing facility in Wrexham, North Wales (UK). "Serum has identified two vaccines and we plan to manufacture these products within the next 12 months after exhibit batches and regulatory approval is received," Wockhardt Managing Director and Global CEO Murtaza Khorakiwala said in an analyst call. Elaborating on the tie-up, he noted that the company has already concluded an agreement with Serum and as a result of that Wockhardt has received 10 million pounds as a contribution for reserving the manufacturing facility for 150 million doses per year of vaccine for 15 years. "This is 150 million doses per year for about a 15-year agreement. And in addition to a contract manufacturing, there is a joint venture .. WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and further to our communication dated February 21, 2023, please find enclosed transcript of the investor call. Wockhardt in talks to ink partnership for vaccines in the UK
Phase III clinical trials of prospective novel antibiotic WCK5222 initiated in Europe: Dr Habil Khorakiwala WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and further to our communication dated February 14, 2023, we enclose herewith the Investor Presentation discussed during Investor Call held today i.e. Tuesday, February 21, 2023 at 16:00 hrs IST through VC. The Investor Presentation is also available on the website of the Company at the link: https://statutory.wockhardt.com/stock_exchange_disclosures.htm Dr. Habil Khorakiwala (Chairman) and Dr. Murtaza Khorakiwala (Managing Director) participated in the Investor Call. The audio - video recording of the Investor Call has been uploaded on the Company's website and the same can be accessed at the link: https://statutory.wockhardt.com/stock_exchange_disclosures.htm Wockhardt Results Earnings Call for Q3FY23
Conference Call with Wockhardt Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.